Free signup for more
- Track your favorite companies
- Receive email alerts for new filings
- Personalized dashboard of news and more
- Access all data and search results
Filing tables
Filing exhibits
- S-4 Registration of securities issued in business combination transactions
- 5.1 Exhibit 5.1
- 10.7 Exhibit 10.7(B)
- 10.18 Exhibit 10.18
- 10.19 Exhibit 10.19
- 10.20 Exhibit 10.20
- 10.21 Exhibit 10.21
- 10.22 Exhibit 10.22
- 23.1 Exhibit 23.1
- 23.2 Exhibit 23.2
- 99.3 Exhibit 99.3
- 99.5 Exhibit 99.5
- 99.6 Exhibit 99.6
- 99.7 Exhibit 99.7
- 107 Exhibit 107
- Download Excel data file
- View Excel data file
Associated filings
- 29 Jul 22 424B3 Prospectus supplement
- 29 Jul 22 EFFECT Notice of effectiveness
- 26 Jul 22 S-4/A Registration of securities issued in business combination transactions (amended)
-
15 Jun 22 S-4 Registration of securities issued in business combination transactions
LSTA similar filings
- 26 Jul 22 Registration of securities issued in business combination transactions (amended)
- 15 Jun 22 Registration of securities issued in business combination transactions
- 2 Sep 11 Registration of securities issued in business combination transactions
- 3 Dec 10 Registration of securities issued in business combination transactions (amended)
- 30 Nov 10 Registration of securities issued in business combination transactions
Filing view
External links
Exhibit 99.7
CONSENT OF ERKKI RUOSLAHTI
Pursuant to Rule 438 promulgated under the Securities Act of 1933, as amended, the undersigned hereby consents to be named in the Registration Statement on Form S-4 of Caladrius Biosciences, Inc., a Delaware corporation (the “Company”), and any amendments or supplements thereto, including the prospectus contained therein, as an individual who has agreed to serve as a director of the Company upon completion of the merger, to all references to the undersigned in connection therewith, and to the filing or attachment of this consent as an exhibit to such Registration Statement and any amendment or supplement thereto.
Dated: June 15, 2022
/s/ Erkki Ruoslahti, M.D., Ph.D. | |
Erkki Ruoslahti, M.D., Ph.D. |